After TURBT, Anlotinib Hydrochloride combined with radiotherapy to preserve bladder for treatment of myometrial invasive bladder cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR1900002674

Enrollment

Unknown

Registered

2019-10-16

Start date

2020-01-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Interventions

Case series:Non-intervention

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1, between the ages of 18 and 85, male or female; 2. Clearly diagnosed as myometrial invasive bladder cancer by histopathology and/or cytology; 3. Rejection of chemotherapy after surgery; 4, with measurable lesions (spiral CT scan greater than 10mm, meet the RECIST1.1 standard); 5. The patient has an estimated KPS score of 70 or more; 6. The estimated survival period >=3 months.

Exclusion criteria

Exclusion criteria: 1. End-stage patients cannot tolerate treatment; 2. The assessment of chronic combined basic diseases may interfere with treatment; 3. Combined with severe liver and kidney dysfunction; 4. The tumor has invaded an important blood vessel or a patient who has been judged by the investigator to have major bleeding during the follow-up study; 5. Patients with any signs or history of bleeding physique.

Design outcomes

Primary

Measure	Time frame
Tumor size;	—

Countries

China

Contacts

Public ContactSun Piyun

Liuzhou Chinese Medicine Hospital

85824368@qq.com+86 15577242316

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026